Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial

  • S. Petersenn
    Division of Endocrinology (S.P.), Medical Center, University of Duisburg-Essen, D-45122 Essen, Germany
  • J. Schopohl
    Medizinische Klinik Innenstadt (J.S.), University of Munich, D-80336 Munich, Germany
  • A. Barkan
    Division of Endocrinology (S.P.), Medical Center, University of Duisburg-Essen, D-45122 Essen, Germany
  • P. Mohideen
    Novartis Pharmaceuticals Corporation (P.M., Y.-Y.H., K.H.), East Hanover, New Jersey 07936
  • A. Colao
    Department of Molecular and Clinical Endocrinology and Oncology (A.C.), University Federico II, I-80125 Naples, Italy
  • R. Abs
    Department of Endocrinology (R.A.), University of Antwerp, BE-2000 Antwerpen, Belgium
  • A. Buchelt
    University of Michigan Medical Center (A.B.), Ann Arbor, Michigan 48109
  • Y.-Y. Ho
    Novartis Pharmaceuticals Corporation (P.M., Y.-Y.H., K.H.), East Hanover, New Jersey 07936
  • K. Hu
    Division of Endocrinology (S.P.), Medical Center, University of Duisburg-Essen, D-45122 Essen, Germany
  • A. J. Farrall
    University of Edinburgh (A.J.F.), Western General Hospital, Edinburgh EH4 2XU, UK
  • S. Melmed
    Cedars-Sinai Medical Center (S.M.), Los Angeles, California 90048
  • B. M. K. Biller
    Neuroendocrine Clinical Center (B.M.K.B.), Massachusetts General Hospital, Boston, Massachusetts 02114

書誌事項

公開日
2010-06-01
DOI
  • 10.1210/jc.2009-2272
公開者
The Endocrine Society

この論文をさがす

収録刊行物

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ